On September 17, 2021 Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, reported its Vice President of Business of Development Dr. Sari Fishman will participate in three upcoming conferences to conduct meetings with potential development and commercialization partners for the Company’s portfolio of drug candidates (Press release, Can-Fite BioPharma, SEP 17, 2021, View Source [SID1234587898]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details are below:

BioPharm America 2021

Virtual Conference: part of Biotech Week Boston

Date: September 20 – 23, 2021

TAP Diabetes 2021

Virtual Conference: Therapeutics Area Partnership (TAP) specialized partnering event for diabetes

Date: October 5 – 7, 2021

BIO-Europe 2021

Virtual Conference: bringing global biopharma together to build partnerships that facilitate innovation

Date: October 25 – 29, 2021

Can-Fite currently has out-licensing agreements for its Namodenoson and Piclidenoson drug candidates in several territories and has received approximately $20 million in upfront and milestone payments to date with additional potential milestone payments of up to approximately $130 million, plus double-digit royalties on net sales following regulatory approval.